Background
==========

Pancreatic cancer is increasing rapidly worldwide and the prognosis is still quite poor even if the patient undergoes curative resection \[[@B1]\]. Compared to conventional 5-fluorouracil (5FU)-based chemotherapies \[[@B2]\], gemcitabine (GEM) showed improved prognosis of patients with non-resectable advanced pancreatic cancer in a randomized trial \[[@B3]\]. Subsequently, studies on adjuvant chemotherapy with 5FU and/or GEM for patients with resectable pancreatic cancer have been reported \[[@B4]-[@B9]\].

Thereafter, in our institution, adjuvant GEM chemotherapy with the standard regimen for patients with resectable pancreatic cancer had been used from 2001 to 2003. However, the compliance rate was very low, 38%, due to severe side effects, such as gastrointestinal discomforts and emaciation, even though the adjuvant chemotherapy was adjusted according to the reduction and extension criteria. The majority of pancreatic cancer patients, over 40 cases, failed to continue the adjuvant GEM chemotherapy with the standard regimen, and died without obtaining the beneficial effects of GEM. From the bitter experience of the low compliance rate in our institution, we hypothesized that the dose intensity of adjuvant GEM chemotherapy with the standard regimen was too heavy and harmful for people of Asian descent, and a milder dose-intensity of adjuvant GEM chemotherapy with bi-weekly administration might be more suitable and lead to prolongation of DFS and/or OS without impairing patients' QOL.

Thereby, after a phase I study, we studied whether mild dose-intensity adjuvant chemotherapy with bi-weekly GEM administration could provide prolonged disease-free survival (DFS) and/or overall survival (OS) without impairing patients' quality of life (QOL).

Methods
=======

After approval from the IRB (the ethics committee for biomedical research) in our university, a phase I study of adjuvant bi-weekly GEM chemotherapy was conducted in our institute using three different doses: a high dose (1,200 mg/m^2^), a medium dose (1,000 mg/m^2^), and a low dose (800 mg/m^2^). Each dose group consisted of at least six patients; the compliance rate in the high dose group was low, 47%, while the rates in the middle and low dose groups were 96% and 97%. Moreover, there was no significant difference in the side effects between the middle and low dose groups according to the common toxicity criteria of the ECOG. Consequently, the appropriate dose-intensity of adjuvant bi-weekly GEM chemotherapy was set at 1,000 mg/m^2^ in our institute. During a five-year period between 2004 and 2009, 128 patients with ductal pancreatic carcinomas were treated with surgery in our institution. A clinical study of mild dose-intensity, adjuvant bi-weekly GEM chemotherapy was performed with a total of 58 pancreatic cancer patients (Group A), who gave informed consent (IC). On the other hand, 36 patients (Group B), who did not give IC for adjuvant bi-weekly GEM chemotherapy, chose 5FU-based chemotherapy as the traditional adjuvant treatment. The remaining 34 patients were excluded from this study due to: macroscopic non-curative surgical treatment (22 cases), previous treatment of the current disease with more than one chemotherapeutic regimen and/or radiotherapy (3 cases), major complications after surgery such as aspiration pneumonia and/or leakage of pancreatojejunostomy (2 cases), hospital death after aggressive progression of the disease (1 case), not less than 85 years old (1 case), not providing IC for adjuvant chemotherapy (1 case), and physical conditions: active infection (1 case), interstitial pneumonia or pulmonary fibrosis (1 case), myocardial infarction within 3 months (1 case), and concomitant advanced cancer (1 case).

In Group A, the first administration of 1,000 mg/m^2^ of GEM was given during the third week after surgery, that is, 15--21 postoperative days (POD) if the patient's condition was favorable. One cycle of this regimen was defined as twice bi-weekly administrations of GEM. After discharge from our hospital, administration of 1,000 mg/m^2^ of GEM was given consecutively to the outpatients at bi-weekly intervals, for at least six full cycles or until the patient's condition was considered tolerable. If severe side effects occurred, the 1,000 mg/m^2^ dosage of GEM was reduced to 800 mg/m^2^. These severe side effects were: leukopenia \<1,000 / mm^-3^, decreasing platelets \<20,000 / mm^-3^, neutrophils \<1,000 / mm^-3^ with fever (\>38°C) or infection, and non-hematologic toxicity higher than Grade 3 according to the common toxicity criteria of the ECOG except for gastrointestinal toxicity, such as nausea, vomiting, diarrhea, and stomatitis. Additionally, when there were multiple side effects, the administration of GEM was extended until the patient's recovery. If recovery needed more than two weeks, the study was discontinued. The multiple side effects were: leukopenia \<2,000 / mm^-3^, decreasing platelets \<70,000 / mm^-3^, and non-hematologic toxicity higher than Grade 2 according to the common toxicity criteria of the ECOG except for gastrointestinal toxicity, such as nausea, vomiting, diarrhea, and stomatitis.

In Group B, the postoperative patients were treated with adjuvant 5FU-based chemotherapy consisting of an intravenous 20 mg/m^2^ bolus of leucovorin followed by an intravenous 400 mg/m^2^ bolus of fluorouracil given on each 5 consecutive days every 28 days for 6 cycles. The adjuvant 5FU-based chemotherapy was also started during the third week after surgery, the same as Group A. When recurrence was identified in Group B, the adjuvant chemotherapy was converted from 5FU-based to standard GEM administration (1,000 mg/m^2^ on days 1, 8, and 15, repeated every four weeks for a total of at least six courses) as for the patients who had agreed with the therapy alteration.

The patients in both groups were followed up carefully, especially for side effects from the agents, disease recurrence, and the patients' QOL, as measured according to the European Organisation for Research and Treatment of Cancer's (EORTC) quality of life questionnaire (quality of life questionnaire -- core 30 or QLQ-C30) and the pancreatic cancer-specific supplemental module (quality of life questionnaire -- pancreatic cancer module 26 or QLQ-PAN26) \[[@B10]-[@B13]\]. The assessment of patients' QOL in both groups was carried out at each outpatient appointment. Postoperative surveillance for the recurrence of pancreatic cancer was undertaken every three months.

Thus, the 58 cases in Group A were compared to the 36 cases in Group B retrospectively. Statistical analysis was performed using student's t-test, the chi-square test, the Mann--Whitney test, the log-rank test, the Kaplan--Meier method, and the Cox hazard proportional model. Results were considered to be statistically significant when *P* \< 0.05.

Results
=======

The patients' ages in Group A ranged from 34 to 82 (median 68.0) years, the patients' other characteristics such as sex, operative procedure, primary tumor size, nodal status, resection status, and the UICC's TNM classification \[[@B14]\] are displayed in Table [1](#T1){ref-type="table"}. Of the patients in Group A, 54 were able to receive every bi-weekly adjuvant chemotherapy treatment of 1,000 mg/m^2^ of GEM, although the other four patients needed an occasional extension of administration interval from bi- to tri-weekly, not because of hematologic toxicity but because of their suboptimal physical status.

###### 

Characteristics of eligible patients

                         **Group A (*n*= 58)**          **Group B (*n*= 36)**          ***P*value**
  ---------------------- ----------------------- ------ ----------------------- ------ --------------
  Age (years)                                                                           
    Median               68                             69.5                           0.07
    Range                34--82                         50--84                          
  Sex                                                                                   
    Male                 36                      62.1   20                      55.6   0.32
    Female               22                      37.9   16                      44.4    
  Operative procedure                                                                   
    PD^a^                45                      77.6   26                      72.2   0.36
    DP^b^                13                      22.4   10                      27.8    
  Primary tumor size                                                                    
    T1                   3                       5.2    1                       2.8     
    T2                   8                       13.8   8                       22.2   0.47
    T3                   36                      62.1   21                      58.3    
    T4                   11                      19.0   6                       16.7    
  Nodal status                                                                          
    N0                   27                      46.6   15                      41.7   0.45
    N1                   31                      53.4   21                      58.3    
  Resection status ^c^                                                                  
    R0                   38                      65.5   22                      61.1   0.49
    R1                   20                      34.5   14                      38.9    
  UICC stage ^d^                                                                        
    I                    10                      17.2   7                       19.4    
    II                   27                      46.6   15                      41.7   0.38
    III                  7                       12.1   4                       11.1    
    IV                   14                      24.1   10                      27.8    
  Histology                                                                             
    Adenocarcinoma       54                      93.1   33                      91.7   0.69
    Other                4                       6.9    3                       8.3     

^a^ Pancreatoduodenectomy, ^b^ distal pancreatectomy, ^c^ R0 or R1 means negative or positive margin microscopically, ^d^ sixth edition of International Union Against Cancer stages.

The patients' age in Group B varied from 50 to 84 (median 69.5) years and the patients' other characteristics are also indicated in Table [1](#T1){ref-type="table"}. There were no statistical differences between both groups in the characteristics of the eligible patients. Except when during the implementation of the standard GEM administration as the second line of chemotherapy for the patients with recurrence disease in Group B, no severe side effects (higher than Grade 2 according to the common toxicity criteria of the ECOG) were observed. Ultimately, 30 cases of the 36 patients in Group B (83.3%) were converted from traditional 5FU-based chemotherapy to GEM administration with the standard regimen due to the recurrence of pancreatic cancer.

Only 11 patients in Group B were able to receive continuously the second line of standard GEM chemotherapy until they collapsed; accordingly, the compliance rate of the standard GEM chemotherapy in this study was low, 36.7% (11/30). Consequently, the total compliance rate in Group B was 47.2% (17/36). Compared with the low compliance rate in Group B, most of the patients in Group A continuously received the adjuvant bi-weekly GEM chemotherapy with a 93% (54/58) compliance rate until their acceptable physical status.

The QOL of patients in Group A was immensely better than that of patients in Group B, in which most of the patients converted to the standard GEM chemotherapy (*P* \< 0.05), especially for fatigue, nausea and vomiting, diarrhea, and difficulty gaining weight in the symptom scales (Table [2](#T2){ref-type="table"}).

###### 

Assessment of patients' quality of life

                                  **Group A (*n*= 58)**   **Group B (*n*= 36)**  ***P*value**
  ------------------------------ ----------------------- ----------------------- --------------
  Functional scales, mean ± SD                                                    
  Physical status                      69.5 ± 31.3             67.8 ± 33.4       NS
  Working ability                      58.6 ± 40.1             55.4 ± 42.2       NS
  Cognitive functioning                67.5 ± 34.8             66.1 ± 36.6       NS
  Emotional functioning                62.3 ± 38.6             59.4 ± 28.5       NS
  Social functioning                   58.1 ± 32.5             53.3 ± 39.7       NS
  Global quality of life               61.9 ± 33.3             51.7 ± 37.0       NS
  Symptom scales, mean ± SD                                                       
  Fatigue                              48.9 ± 32.1             68.1 ± 36.3       *P* \< 0.05
  Nausea and vomiting                  26.8 ± 20.4             53.7 ± 32.6       *P* \< 0.05
  Pain                                 36.2 ± 28.5             34.2 ± 30.9       NS
  Dyspnea                              22.0 ± 27.9             32.2 ± 22.8       NS
  Insomnia                             55.7 ± 38.7             61.1 ± 41.7       NS
  Appetite loss                        33.3 ± 36.1             43.3 ± 39.1       NS
  Constipation                         23.8 ± 31.8             26.4 ± 30.4       NS
  Diarrhea                             21.0 ± 22.6             53.9 ± 38.5       *P* \< 0.05
  Financial difficulties               52.3 ± 37.3             58.8 ± 40.4       NS
  Pancreas-specific pain               44.4 ± 29.2             49.5 ± 36.6       NS
  Diet restriction                     42.5 ± 32.0             54.1 ± 37.8       NS
  Jaundice and pruritus                12.7 ± 20.1             18.8 ± 19.9       NS
  Steatorrhea                          36.1 ± 30.4             39.1 ± 34.7       NS
  Poor body image                      38.3 ± 34.2             59.8 ± 35.0       NS
  Sexual dysfunction                   66.8 ± 35.8             75.3 ± 41.1       NS
  Dissatisfaction with care            61.2 ± 37.7             65.6 ± 39.1       NS
  Bloating                             41.7 ± 31.5             49.7 ± 37.4       NS
  Bad-tasting food                     29.4 ± 36.9             37.4 ± 38.2       NS
  Indigestion                          30.7 ± 30.1             39.5 ± 28.6       NS
  Flatulence                           35.7 ± 31.5             38.0 ± 32.3       NS
  Difficulty gaining weight            49.5 ± 34.4             67.7 ± 40.5       *P* \< 0.05
  Weakness                             45.9 ± 32.8             56.6 ± 42.7       NS
  Dry mouth                            40.5 ± 38.0             49.1 ± 36.9       NS
  Treatment side-effects               39.1 ± 30.5             46.2 ± 33.8       NS
  Worry about future                   57.8 ± 35.8             66.3 ± 27.6       NS
  Difficulty planning                  34.6 ± 33.7             46.8 ± 45.2       NS

*SD* standard deviation; *NS* no significant difference.

The median DFS of Group A was significantly improved in contrast with Group B (12.5 versus 6.6 months, *P* \< 0.001, Figure [1](#F1){ref-type="fig"}). As shown in Figure [2](#F2){ref-type="fig"}, each median OS was 20.2 months in Group A versus 11.9 months in Group B, and each three-year OS rate was 24.0% in Group A versus 4.8% in Group B, suggesting that there was a significant difference between the two groups statistically (*P* \< 0.005). When OS for patients at Stages 0--IIa and IIb--IV is compared between Groups A and B, a statistical difference was observed in each of the classified stages (Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). The median survival of living patients was 52.1 months in Group A (*n* = 7) versus 28.7 months in Group B (*n* = 2). The longest survival time in Group A was over 6.7 years (80.4 months) while for Group B it was over 3.0 years (36.1 months). However, for the other patients, 51 in Group A and 34 in Group B died of recurrences of pancreatic cancer due to peritonitis carcinomatosa or multiple distant metastases in the liver, bone, and/or lung.

![**Disease-free survival (DFS) of resected pancreatic cancer patients who received adjuvant chemotherapy with bi-weekly gemcitabine (GEM: Group A) versus 5FU-based (5FU: Group B).** mo., months (Log-rank test *P* \< 0.001).](1477-7819-11-3-1){#F1}

![**Overall survival (OS) of resected pancreatic cancer patients who received adjuvant chemotherapy with bi-weekly gemcitabine (GEM: Group A) versus 5FU-based (5FU: Group B).** mo., months (Log-rank test *P*\< 0.005).](1477-7819-11-3-2){#F2}

![**Comparison of overall survival (OS) for resected pancreatic cancer patients between bi-weekly gemcitabine (GEM: Group A) and 5FU-based (5FU: Group B) in Stage 0--IIa.** mo., months (Log-rank test *P*\< 0.01).](1477-7819-11-3-3){#F3}

![**Comparison of overall survival (OS) for resected pancreatic cancer patients between bi-weekly gemcitabine (GEM: Group A) and 5FU-based (5FU: Group B) in Stage IIb--IV.** mo., months (Log-rank test *P*\< 0.05).](1477-7819-11-3-4){#F4}

Univariate analysis for the subgroups in Table [3](#T3){ref-type="table"} showed that there were no statistical differences between the groups for 69-year-old or under females and T1--2 factors. As shown in Table [4](#T4){ref-type="table"}, multivariate analysis for OS in both groups indicated three statistically important factors: bi-weekly adjuvant GEM chemotherapy, T2 or less, and R0.

###### 

Overall survival in the total entire population and subgroups

                            **Overall survival**                  
  --------------- ---- ---- ---------------------- ------ ------- ----
  All patients    58   36   20.2                   11.9   0.001    
  Age ≦69         38   20   19.7                   12.9   0.061   NS
    \>70          20   16   20.4                   8.6    0.001    
  Sex: male       36   20   20.4                   6.3    0.001    
  Sex: female     22   16   19.8                   12.6   0.094   NS
  T1--2           11   9    36.6                   20.5   0.086   NS
  T3--4           47   27   15.6                   9.4    0.000    
  N0              27   15   21.3                   13.0   0.007    
  N1              31   21   13.6                   7.0    0.017    
  R0              43   28   20.7                   12.5   0.001    
  R1              15   8    13.4                   5.5    0.034    
  Stage 0--IIA    29   13   23.7                   15.4   0.008    
  Stage IIB--IV   29   23   13.4                   7.0    0.043    

*NS* no significant difference.

###### 

Multivariate analysis for overall survival

                        **HR (95% CI)**     ***P*value**
  --------------------- ------------------- --------------
  Treatment with GEM    0.34 (0.20--0.57)   0.0001^a^
  Age \<70              1.09 (0.68--1.77)   0.7104
  Male                  0.89 (0.53--1.48)   0.6490
  T factor ≦T2          0.49 (0.25--0.94)   0.0314^a^
  N factor N0           0.75 (0.26--2.19)   0.6046
  UICC stage ≦VIIA      1.23 (0.36--4.26)   0.7415
  Resection status R0   0.38 (0.20--0.73)   0.0033^a^

^a^Statistically significant difference.

*CI* confidence interval; *GEM* gemcitabine; *HR* hazard ratio.

Discussion
==========

Several successful clinical trials of adjuvant chemotherapy based on 5FU and/or GEM for pancreatic cancer have been published \[[@B15]-[@B25]\]. Moreover, recent prospective, randomized studies of adjuvant GEM chemotherapy suggested an improvement in DFS and/or OS of pancreatic cancer patients \[[@B26]-[@B31]\], except for the ESPAC-3 trial \[[@B32]\]. Thus, adjuvant chemotherapy using GEM for pancreatic cancer has been recognized as an effective treatment. Although it was an adjuvant GEM trial, CONKO-001 indicated prolonged OS of pancreatic cancer patients and unsatisfied compliance (less than 62%) of GEM administration with the standard regimen was also reported \[[@B26]\]. In general, it has been thought that the main purpose of adjuvant chemotherapy is prolongation of DFS and/or OS by preventing or delaying disease relapse without impairing patients' QOL. Previously, we had experienced that GEM administration with the standard regimen led to an unsatisfied compliance rate of 38% for pancreatic cancer patients after surgery. The patients suffered from severe side effects (over Grade 3) and had reduced QOL. Thus, the compliance rate generally seemed to be intimately correlated with patients' QOL. Therefore, in terms of reducing toxicity, increasing compliance rate, and obtaining acceptable QOL, a phase I study was carried out in our department to determine an optimal dose-intensity of adjuvant GEM chemotherapy. After the phase I trial, in which the optimal dose-intensity was set at bi-weekly 1,000 mg/m^2^ of GEM administration, this trial studied whether the optimal, medium dose-intensity adjuvant bi-weekly GEM chemotherapy for pancreatic cancer patients would obtain both prolongation of OS and satisfactory compliance, that is, the patients' QOL was studied to see if it was acceptable.

Results from this clinical study suggest that the adjuvant bi-weekly chemotherapy with 1,000 mg/m^2^ of GEM (Group A) statistically prolonged DFS and OS for pancreatic cancer patients when compared with the adjuvant 5FU-based chemotherapy (Group B) as a whole and in Stage 0--IIa and Stage IIb--IV subgroups. Thus, the adjuvant bi-weekly GEM chemotherapy was more effective than the 5FU-based treatment in resected pancreatic cancer patients even though most patients in Group B converted to the standard GEM chemotherapy due to the recurrence of pancreatic cancer. Previously, it had been reported in a Norwegian randomized study \[[@B2]\], ESPAC-1, and other trials \[[@B7]-[@B9],[@B15],[@B16]\] that adjuvant chemotherapies using 5FU for resectable pancreatic cancer led to significant survival benefit. On the other hand, results from a phase III trial conducted by the EORTC on the gastrointestinal tract cancer cooperative group and two Japanese adjuvant chemotherapy studies indicated that 5FU could not achieve such a survival advantage \[[@B5],[@B33],[@B34]\]. The RTOG 97--04 study indicated that GEM was superior to 5FU as an adjuvant chemoradiotherapy agent \[[@B27],[@B28]\]. Results from this study also supported the potency of GEM compared to 5FU. The compliance rate of Group A in this study was higher than that of CONKO-001 study \[[@B26]\] in which GEM was given with the standard regimen (93% versus 62%). According to EORTC QLQ-C30 and QLQ-PAN26, the QOL of patients in Group A was much better than that of Group B, suggesting that our administration rate and dosage of GEM, that is, the medium dose-intensity, were tolerable and applicable even to patients with pancreatic cancer following major surgery. The results of the univariate analysis shown in Table [3](#T3){ref-type="table"} implied that the malignancy potential of the tumors was stronger in the younger generation, the effectiveness of gemcitabine was less in females than males, and for smaller tumors the surgical treatment had a greater affect than adjuvant chemotherapy. The multivariate analysis shown in Table [4](#T4){ref-type="table"} suggested that early detection of pancreatic cancer, good curability, and adjuvant chemotherapy with bi-weekly GEM were important to obtain a prolonged OS, such as that for the previous standard of GEM chemotherapy.

Currently, combination chemotherapy of GEM with new agents, such as capecitabine, erlotinib, or bevacizumab, has been used to try to improve the poor survival rate of patients with advanced pancreatic cancer \[[@B35]-[@B41]\]. More recently, combination therapies using peptide vaccines with GEM, which have achieved striking tumor reduction in advanced pancreatic cancer patients, have been reported \[[@B42]-[@B46]\]. Nowadays, ongoing adjuvant chemotherapy trials, such as JASPAC-01 (GEM versus S-1), ESPAC-4 (GEM versus GEM+capecitabine), CONKO-005 (GEM versus GEM+erlotinib), and CONKO-006 (GEM versus GEM+sorafenib) are under trial \[[@B47]-[@B54]\]. These new approaches may be able to obtain better prognosis in patients after curative resection of pancreatic cancer. However, it seems likely that good QOL is as important a factor for resected pancreatic cancer patients as prolongation of OS.

Conclusions
===========

In conclusion, the medium dose-intensity adjuvant chemotherapy with bi-weekly GEM led to improved OS with acceptable QOL in pancreatic cancer patients after surgery.
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